Related Articles
BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML
Dynein axonemal heavy chain 9 M4374I variation may have an effect on imatinib mesylate resistance in CML
Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib‑based therapy
Semi‑random mutagenesis profile of BCR‑ABL during imatinib resistance acquirement in K562 cells
Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target